Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00999206 | Study Measuring the Safety, Immunogenicity and Lot Consistency of Cell Derived Influenza Vaccine | PHASE3 | COMPLETED | 3,138 | — | — | Jan 1, 2010 | Aug 1, 2010 | Aug 26, 2011 | 19 | Australia, New Zealand |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Influenza Vaccine | BIOLOGICAL | surface antigen, inactivated, prepared in cell cultures |
Inclusion Criteria 1. Female or male subjects \>= 18 years of age (adults \>= 18 to \< =60 years of age or elderly \>= 61 years of age). 2. Willing and able to give informed consent before any protocol procedures are performed. 3. Able to adhere to visit schedules and all protocol required study pr...